Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFA plus camrelizumab versus RFA alone in hepatocellular carcinoma
ChiCTR2000039093Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of camrelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: progression-free survival rate. Started Oct 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000039093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039093.